Discussion stirs around BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) this week; here is what analysts are saying.

June 7, 2018 - By Darrin Black

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) LogoInvestors sentiment decreased to 0.96 in 2018 Q1. Its down 0.25, from 1.21 in 2017Q4. It turned negative, as 38 investors sold BioMarin Pharmaceutical Inc. shares while 124 reduced holdings. 36 funds opened positions while 119 raised stakes. 174.46 million shares or 1.43% more from 172.01 million shares in 2017Q4 were reported.
California Pub Employees Retirement Systems accumulated 346,100 shares. Bedell Frazier Invest Counseling Lc invested in 35,580 shares or 1.02% of the stock. Sei invested 0.05% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). The New Jersey-based Lord Abbett Communications Limited Liability Corporation has invested 0.02% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Regions Financial Corp accumulated 2,297 shares. Sectoral Asset Mgmt has 3.54% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Primecap Ca has 13.77M shares for 0.84% of their portfolio. Stifel Finance Corp reported 9,421 shares stake. Scout Invs owns 94,914 shares for 0.18% of their portfolio. Moreover, Gateway Invest Advisers Ltd Com has 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 13,948 shares. Arrowgrass Prns (Us) Limited Partnership has invested 0.68% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Sands Management Ltd Llc reported 7.25 million shares or 1.74% of all its holdings. Capstone Invest Advisors Ltd Liability Com has 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Ardsley Advisory Partners holds 0.12% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 10,000 shares. Fort Washington Investment Oh, a Ohio-based fund reported 4,790 shares.

Since December 14, 2017, it had 0 buys, and 26 selling transactions for $25.15 million activity. $244,863 worth of stock was sold by Ajer Jeffrey Robert on Friday, March 9. 11,059 shares were sold by SPIEGELMAN DANIEL K, worth $908,497 on Monday, April 23. Shares for $272,523 were sold by Davis George Eric. Another trade for 800 shares valued at $71,116 was sold by HERON ELAINE J. FUCHS HENRY J also sold $801,200 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Monday, April 2. 3,750 shares were sold by LAWLIS V BRYAN, worth $318,750.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Among 13 analysts covering Biomarin Pharmaceutical (NASDAQ:BMRN), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. Biomarin Pharmaceutical had 24 analyst reports since December 14, 2017 according to SRatingsIntel. Credit Suisse maintained the shares of BMRN in report on Friday, May 25 with “Outperform” rating. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Hold” rating given on Tuesday, February 27 by RBC Capital Markets. Leerink Swann maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Monday, May 7. Leerink Swann has “Buy” rating and $14500 target. On Wednesday, January 24 the stock rating was maintained by JP Morgan with “Outperform”. On Tuesday, May 15 the stock rating was maintained by Wedbush with “Buy”. Bernstein maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Monday, April 30 with “Hold” rating. The firm has “Buy” rating by Canaccord Genuity given on Friday, May 25. The firm has “Outperform” rating by Wedbush given on Thursday, December 14. The rating was maintained by Wedbush with “Buy” on Wednesday, December 20. Wedbush maintained it with “Buy” rating and $110.0 target in Monday, March 12 report. Below is a list of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) latest ratings and price target changes.

31/05/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $127 New Target: $133 Maintain
29/05/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $112 New Target: $115 Maintain
25/05/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $116 New Target: $120 Maintain
25/05/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $101 New Target: $105 Maintain
21/05/2018 Broker: Wedbush Rating: Buy New Target: $112.0000 Maintain
15/05/2018 Broker: Wedbush Rating: Buy New Target: $112.0000 Maintain
16/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $101 Initiates Coverage On
07/05/2018 Broker: Leerink Swann Rating: Buy New Target: $145.0000 Maintain
30/04/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $112 New Target: $113 Maintain
30/04/2018 Broker: Bernstein Rating: Hold New Target: $92.0000 Maintain

The stock decreased 1.96% or $1.81 during the last trading session, reaching $90.43. About 435,920 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 5.91% since June 7, 2017 and is uptrending. It has underperformed by 6.66% the S&P500.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $15.98 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Streetinsider.com which released: “Viking Global’s 13F Shows New Stakes in Alibaba (BABA), BioMarin (BMRN) and Western Digital (WDC), Increase in …” on May 15, 2018, also Seekingalpha.com with their article: “BioMarin’s valoctocogene roxaparvovec shows long-term treatment effect in hemophilia A study” published on May 22, 2018, Profitconfidential.com published: “This Is Why Higher BMRN Stock Prices Are on the Horizon” on May 28, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: Bizjournals.com and their article: “Why this biotech exec broke down on a conference call over company’s new rare-disease drug” published on May 31, 2018 as well as Seekingalpha.com‘s news article titled: “BioMarin +5% on FDA approval of metabolic disorder treatment” with publication date: May 24, 2018.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: